Home / 2021 / May / 13

Daily Archives: May 13, 2021

Constellation Brands Invests in Disruptive Rosé Brand Geared Toward Multicultural Consumers in La Fête Du Rosé

Investment marks first as part of Constellation’s Focus on Minority Founders initiative and commitment to invest $100 million in Black/minority-owned businesses by 2030

La Fête du Rosé Founder Donae Burston Created a Brand to Serve Millennial and Gen Z, Focused on Shared Values, Taste, and Experiences

VICTOR, N.Y., May 13, 2021 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that it has acquired a minority stake in the fast-rising rosé label, La Fête du Rosé – a brand created to cater to diverse drinkers who share common interests across travel, food, experiences, and wine. The investment was made through Constellation’s venture capital group and represents the first company to receive investment dollars as part of Constellation’s Focus on Minority Founders initiative, which plans to invest $100 million in Black, Latinx, and minority-owned businesses by 2030.

“We’re thrilled to jumpstart our Focus on Minority Founders initiative with an investment in a fantastic consumer-oriented brand and with a dynamic and proven industry leader behind it in Donae Burston,” said Bill Newlands, Constellation’s president and chief executive officer. “Minority-owned businesses are under-represented in our industry and there is a real need to make it more equitable for those businesses to receive access to capital. This initiative enables us to play a role in creating greater equity within our industry and provides an opportunity for us to work with bold leaders and brands with unique value propositions that align with our premiumization strategy. La Fête du Rosé is certainly that, as Donae has taken a consumer-first approach to building a distinctive rosé brand that authentically reflects today’s multicultural consumer values.”

Founded in 2019 by Burston, a 15-year beverage industry veteran, La Fête du Rosé was inspired by the popularity of rosé in the French peninsula of Saint Tropez but built with the intention of a fresh, modern, and inclusive brand geared toward rosé drinkers of all backgrounds.

“People like to see themselves in anything, and that’s what we’re trying to do with La Fête du Rosé – create an exceptional liquid and brand that’s focused on reaching a wider audience,” said Burston, founder & CEO of La Fête du Rosé. “It has taken a lot of hard work to get the brand to where it is today. Constellation Brands is the right partner to allow us to scale the brand in a way that stays true to its ethos.”

La Fête du Rosé – which translates to “the rosé party” – is produced in conjunction with prestigious winemakers from Domaine Bertaud Belieu, the oldest vineyard on the Saint Tropez peninsula established in 1340. The delicious pink wine is known for its refreshing taste, light alcohol content, and drinkability.

Since its debut, the brand has donated a portion of its proceeds to various programs that send disadvantaged and underrepresented youth on unique travel experiences and to organizations focused on advancing racial justice and creating opportunities for people of color in the wine & spirits industry.

“Donae and the La Fête du Rosé team have created a truly unique and distinctive lifestyle brand, and we’re excited to collaborate with them and share insights to fuel our collective growth,” said Jennifer Evans, vice president, Constellation Ventures. “We look forward to making future investments behind our Focus on Minority Founders initiative and working with brands and companies that align with our strategy of investing in emerging, higher-end brands that have a point of differentiation in the marketplace.”

A component of Constellation’s multi-initiative racial justice action plan aimed at achieving greater equity for African American/Black and minority colleagues at Constellation, within the beverage alcohol industry, and within the communities where the company operates, Focus on Minority Founders will support the growth and development of Black and minority-owned businesses by providing funding and access to sales, marketing, operations, and finance expertise through the Constellation Brands Ventures team and Constellation’s many subject matter experts.

Earlier this year, Constellation announced a $10 million investment commitment through Focus on Minority Founders in the Clear Vision Impact Fund, LP — a newly-formed investment vehicle founded by Siebert Williams Shank & Co., LLC, with an objective of making investments in minority-owned businesses, with an emphasis on African American/Black-owned businesses.

The initiative is inspired by the success of Constellation’s Focus on Female Founders program, which is committed to investing $100 million in female-owned and founded companies. Since its launch in 2018, Constellation’s Ventures portfolio mix has shifted from 20% female-owned to more than 50% female-owned, reinforcing the need for these initiatives and showing the measurable improvement they can make in promoting greater equity within the beverage alcohol industry.

The Focus on Minority Founders application can be found on cbrands.com/story/ventures, and the evaluation process aligns with Constellation’s ventures strategy of investing in emerging, unique and distinctive brands. Constellation Brands Ventures continues to look for brands that have a point of differentiation in the market; companies that want to welcome Constellation Ventures as an active minority investor; organizations looking to grow beyond their current markets; and entrepreneurs who want to grow their business with the support of Constellation’s investment, mentorship, and involvement.

Terms of the transaction have not been disclosed.

ABOUT CONSTELLATION BRANDS
At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard work, and the bold calculated risks we take to deliver more for our consumers, trade partners, shareholders, and communities in which we live and work. It’s what has made us one of the fastest-growing large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Today, we are a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Every day, people reach for our high-end, iconic imported beer brands such as Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, and Pacifico, and our high-quality premium wine and spirits brands, including the Robert Mondavi brand family, Kim Crawford, Meiomi, The Prisoner brand family, SVEDKA Vodka, Casa Noble Tequila, and High West Whiskey.

But we won’t stop here. Our visionary leadership team and passionate employees from barrel room to boardroom are reaching for the next level, to explore the boundaries of the beverage alcohol industry and beyond. Join us in discovering what’s Worth Reaching For.

To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

MEDIA CONTACTS INVESTOR RELATIONS CONTACTS
Mike McGrew 773-251-4934 / michael.mcgrew@cbrands.com
Amy Martin 585-678-7141 / amy.martin@cbrands.com
Patty Yahn-Urlaub 585-678-7483 / patty.yahn-urlaub@cbrands.com
Marisa Pepelea 312-741-2316 / marisa.pepelea@cbrands.com

A downloadable PDF copy of this news release can be found here http://ml.globenewswire.com/Resource/Download/dc73605f-ecfe-460e-980e-74ac547b2b16

Brunswick Exploration Options New Discovery Adjacent to the Fundy Gold Project

MONTREAL, May 13, 2021 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (“BRW” or the “Company”) is pleased to announce that is has signed an amendment to the option agreement made in October 27th 2020 with prospector Robert Murray to acquire a 100% interest in the Menzies Lake Claim (“Property”), located 20 kilometers west of the City of Saint John, New Brunswick. The Property is adjacent to the Fundy Gold project and hosts a new vein grab sample discovery grading 70.40 g/t Au, 20.0 g/t Ag and 0.28% Cu in close proximity to the highly prospective Spruce Lake Shear Zone (Figure 1).

Mr. Killian Charles, President of BRW, commented: “We are very pleased to further consolidate our Fundy Gold project and work with Rob on another exciting greenfield discovery in southern New Brunswick. The mineralization is interpreted to be near the Spruce Lake Shear Zone which is host to the 67.2 g/t Au discovery announced at Little Lepreau in 2020. Company prospectors have arrived at Fundy Gold and will initially follow-up on anomalous soils results from our 2020 grid (see Press Release dated March 17 2021).”

Menzies Lake Overview

The total Property comprises 27 units with a total surface area of 614 hectares (6.14 square kilometres). The grab sample mineralization is hosted in an outcrop with abundant quartz carbonate veins within the Ludgate Lake Granodiorite. The Spruce Lake Shear Zone is believed to be the fluid conduit for mineralization at the Little Lepreau discovery extending to Shadow Lake and Menzies Lake, for a strike length of roughly 16 kilometers.

Highlight of the bedrock sample on the property is:

Sample ID Au g/t Ag g/t Cu ppm
ML36 70.40 20 2830

Option Amendment and Purchase Terms (All dollar figures in Canadian dollars)

Brunswick Exploration has amended the Option Agreement with Robert Murray (See Press Release dated October 27th 2020). The amended payment schedule which includes the October 27, 2020 claims as well as Menzies Lake is as follows:

  • An option payment of $10,000, upon the closing of the formal agreement (Paid);
  • An option payment of $10,000, upon closing of the Amendment (Paid);
  • An option payment of $22,500 and share payment of 12,000 shares on or before the 1st year anniversary of the effective date
  • An option payment of $22,500 and share payment of 22,000 shares on or before the 2nd year anniversary of the effective date
  • An option payment of $22,500 and share payment of 22,000 shares on or before the 3rd year anniversary of the effective date
  • An option payment of $32,500 and share payment of 54,000 shares on or before the 4th year anniversary of the effective date
  • An option payment of $35,000 and share payment of 110,000 shares on or before the 5th year anniversary of the effective date

The schedule can be accelerated at BRW’s discretion. The Menzies Lake claims are subject to the same 2% NSR terms as outlined in the October 27, 2020 Option Agreement. The first half (1%) of the NSR may be repurchased upon payment of $1,000,000 from BRW and the second half (1%) of the NSR may be repurchased upon payment of $2,000,000.

Qualified Person

The scientific and technical information contained in this press release has been reviewed and approved by Mr. Charles Kodors, P. Geo, Manager New Brunswick of Brunswick Exploration.

About Brunswick Exploration

The Company, formerly Komet Resources Inc. is a Montreal-based mineral exploration venture listed on the TSX-V under symbol BRW. The Company is focused on exploration and development of gold and base metal properties in Eastern Canada. Current projects include gold-polymetallic vein systems in Southern New Brunswick (Fundy Gold Project), base metals VMS in the Bathurst Camp in northern New Brunswick and in the Chibougamau region of Quebec (Waconichi), and the new Lac Édouard nickel-copper project in Québec.

Investor Relations/information

Mr. Killian Charles, President (kcharles@BRWexplo.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

 

NEP and Asian Tour Media Go Live with First Ever Golf Remote Production in Asia

SINGAPORE, May 12, 2021 (GLOBE NEWSWIRE) — With a successful delivery of HSBC Women’s World Championship golf in Singapore and the Honda LPGA Thailand production as a new proof of concept, NEP Singapore and Asian Tour Media have registered Asia’s first live-to-air remote production.

NEP Singapore is excited about the development and deployment of the best technologies and tools for its clients, and is proud to unveil its new transformational commitment to bring Remote Production to South East Asia.

Saeed Izadi, President of NEP Singapore and India, said: “Innovation is the engine of our progress and I support it with a passion. Our brand focuses on being creative and ambitious — all of the design and implementation were done entirely by our in-house engineers and with the support of our global expertise in NEP. I am very proud of our team, which has enabled us to realize our vision of being pioneers in this innovation.”

Saeed commented that the quality of this production was “exceptionally unmatchable”.

“It has been my dream to set up a remote production hub in South East Asia, but it would not have been possible without the trust that our client, Asian Tour Media, has placed in us. We’re grateful for that,” he added.

Alastair Berry, Managing Director of Asian Tour Media, said: “We needed to have the same production solution for both Singapore and Thailand events, and so the move to remote production was an easy decision to make. We have been working very closely with NEP throughout the last 12 months on this project, so we knew the technology would work. What we didn’t realise was just how good the system was, the technology is amazing.”

Remote Production is a hybrid method of broadcasting, based on Internet Protocol (IP) technology. Locating equipment follows a distributed model in which IP provides the connectivity as opposed to physical cables.

Saeed explains: “Traditionally we used to build TV control rooms with our fly-pack where the event was happening, being a golf course, a cricket stadium, racetrack or any sporting venue. It has always been logistics heavy. With this mould-breaking approach, we are able to reduce the volume of the broadcasting equipment at the venue tremendously, keeping the core of the system at base.”

Environmental responsibility is integral to how NEP operates, and the team at NEP believes addressing global warming requires a collective effort by all industries. Remote Production is more environmentally friendly; furthermore, it addresses the pressing challenge casued by the COVID pandemic to meet safety requirements and provide social distancing, as it allows for crew to collaborate remotely and while based on different locations around the globe.

“Thinking of just how many fewer flights are necessary for the entire team, I can confidently claim [that] it will be an effective step towards reducing carbon footprint for us and for our clients and partners,” Saeed states. “Traditionally, big teams were required to be present where the event was taking place. Remote production is a game changer in that regards. And the beauty of it is that the unparalleled premium quality of the feed we are committed to provide to our client is not sacrificed.”

Completion of this event marks an important step forward in NEP’s strategic goal to become the worldwide leader in Centralised (Remote) Production and to deliver an expanding portfolio of cloud-based and virtualized production solutions and products. The company has an expanding network of connected centralised production facilities and datacenters around the world, and it will continue to expand this network over the coming year.

For more information, please visit https://www.nepgroup.sg/.

About NEP

For over 30 years, NEP has been the leading worldwide technical production partner helping premier content producers bring live sports and entertainment to life. Our services include centralized and remote production, specialty capture, RF and wireless video/audio, virtual and in-studio production, audio visual solutions, host broadcast support, post production, connectivity and transmission, premium playout and innovative software-based media management solutions. NEP’s 4,000+ employees are driven by a passion for superior service and a focus on technical innovation. Together, we have supported productions in 88 countries on all seven continents.

NEP is headquartered in the United States and has operations in 25 countries. Learn more at nepgroup.com.

Susan Matis
NEP Group
+1 412 423-1339
press@nepgroup.com

Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress

Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress

May 12, 2021

  • NidlegyTM on track for Phase III European trial in stage IIIB/C melanoma. Opening of additional clinical centers to boost recruitment rate is ongoing. Emerging promising data in non-melanoma skin cancers
  • Fibromun on track for the six ongoing trials in Soft Tissue Sarcoma and High-Grade Glioma
  • Philogen is well capitalized, with cash & cash equivalents of about  120 million
  • Philogen’s management team will hold a webinar to discuss the news on Thursday, 13th May at 10:00am EST / 14:00pm BST / 15:00pm CEST– please find the link to this webinar here

Siena (Italy), 12 May 2021 – (Globe Newswire) – Philogen S.p.A. (BIT:PHIL) – a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce progress updates for its fully-owned immunocytokine and small molecule programs.

We are excited to report for the first time, after our successful Initial Public Offering in March 2021, the progress of our late- and early-stage product candidates,” commented Prof. Dr. Dario Neri, Co-Founder, Chief Executive Officer and Chief Scientific Officer of Philogen S.p.A. “Our most advanced programs are running on trackWith the proceeds of the IPO, Philogen intends to bring NidlegyTM and Fibromun to registration and start direct marketing in certain territories as envisaged in our Business Plan. We are also completing the construction of a second GMP facility in Rosia (Siena), which will further boost our in-house manufacturing capabilities, in anticipation of our expected marketing activities.

NidlegyTM

  • European Phase III trial for the neo-adjuvant treatment of locally advanced Stage IIIB/C melanoma
    • The study has so far recruited 164 out of 214 patients planned for the study
    • Two interim analyses, foreseen by the study protocol, have been successfully passed. The independent Data Safety Monitoring Board has recommended in both occasions a continuation of the trial, without change to the statistical assumptions.
    • Focus on pre-treated patients with locally advanced disease who now receive Nidlegy™ in neo-adjuvant setting prior to surgery
    • Harmonized primary endpoint (Recurrence-Free Survival) in both European and American Phase III clinical trials
    • Expansion of clinical centers (currently 18 centers in Germany, Italy, Poland and France)
  • US Phase III trial for the treatment of locally advanced Stage IIIB/C melanoma
    • Opening of additional clinical centers in the United States
    • Initial activities for the potential expansion of the clinical trial in additional countries, including Australia
  • European Phase II trial for the treatment of non-melanoma skin cancers
    • Encouraging results from a Phase II trial in Europe in patients with non-melanoma skin cancer
    • Current focus on basal cell carcinoma and squamous cell carcinoma of the skin, but potential for additional non-melanoma skin cancers
    • Expansion of the trial to include Poland and Germany, in addition to Switzerland
    • Addition of new centers to speed-up recruitment and collect clinical information in different types of patients, thus facilitating future planning of pivotal trials
    • Ability of Nidlegy™ to induce a rapid necrosis of the injected lesion, with very good tolerability and excellent cosmetic outcome
    • Presentation of initial clinical results at the World Melanoma Congress 2021 (April 14-17, 2021)
  • US Phase II trial for the treatment of Stage IV melanoma
    • Completed submission of a Phase II trial for the treatment of patients with Stage IV melanoma who no longer respond to PD-1 blockade, as previously planned in a Type C meeting with the U.S. Food and Drug Administration (FDA).
    • The study foresees three different treatment groups, all in combination with PD-1 blockade

Fibromun

  • European Phase III trial for the treatment of first line advanced/metastatic Soft Tissue Sarcoma
    • The study is being conducted at German centers, comparing Fibromun and doxorubicin against doxorubicin alone
    • Additional centers are being opened in Germany
    • Opening of centers in Poland, Spain and Italy is currently being planned
    • The ongoing trial is expected to read out by the end of 2023
  • US Phase IIb trial for the treatment of first line metastatic Leiomyosarcoma
    • The study is being conducted at eight centers in the United States
    • Additional centers are being opened in the United States
  • European Phase II trial for the treatment of pretreated advanced/metastatic Soft Tissue Sarcoma
    • The study is being conducted at German centers, involving third and later line patients with advanced Soft Tissue Sarcoma, comparing Fibromun plus dacarbazine against dacarbazine alone
    • The study foresees an initial non-randomized run-in part (in which all patients receive Fibromun plus dacarbazine), followed by a randomized part with two groups of treatment (43 patients per group)
    • Start of the randomized part of the trial expected in Summer 2021
    • Trial has the potential to read out by the end of 2023
  • European Phase I/II trial for the treatment of IDH wildtype WHO Grade III-IV High-Grade Glioma at first recurrence/relapse (monotherapy)
    • Completed recruitment in December 2020 for a Phase I/II trial for the treatment of high-grade glioma patients at first recurrence/relapse, involving monotherapy treatment with Fibromun,
    • Patients are being monitored for survival, with promising interim results compared to historical controls
    • Preliminary data published in Science Translational Medicine, with clinical data confirming the pharmacodynamic effects observed in orthotopic animal models of the disease [Weiss et al. (2020) Sci. Transl. Med., 12, eabb2311]
    • Rapid induction of tumor necrosis evidenced by Magnetic Resonance Imaging (MRI).
    • Interim survival reports expected in June 2021 and in December 2021
    • Observed preclinical and clinical data (activity and tolerability) have supported the initiation of clinical trials in first and second line, in combination with the corresponding standards of care
  • European Phase I/II trial for the treatment of Glioblastoma at first recurrence/relapse (in combination with Lomustine)
    • Execution of the trial strongly supported by curative activity observed in orthotopic and immunocompetent mouse models of glioma
    • Trial started in Switzerland, opening of additional centers in other countries planned for the randomized Phase II part of the study
    • Ongoing harmonized regulatory dialogue with European Medicines Agency (EMA) and FDA
  • European Phase I/II/IIb trial for the treatment of newly diagnosed Glioblastoma (in combination with Radiotherapy and Chemotherapy)
    • Execution of the trial strongly supported by curative activity observed in orthotopic and immunocompetent mouse models of glioma
    • Trial started in Switzerland, opening of additional centers in other countries planned for the randomized Phase IIb part of the study
    • On-going harmonized regulatory dialogue with European Medicinal Agency (EMA) and FDA

Darleukin

  • European Phase II trial sponsored by the University of Maastricht for the treatment of limited metastatic non-small cell lung cancer (in combination with anti-PD(L)1 and Stereotactic Ablative Radiotherapy)
    • Strong preclinical rationale for the use of Darleukin (L19IL2) in combination with radiation therapy, established and published for multiple immunocompetent mouse models of cancer
    • On-going randomized Phase II clinical trial in patients with non-small cell lung cancer in combination with stereotactic ablative radiotherapy and PD-(L)1 blockade, following encouraging Phase I results [Van Limbergen et al. (2020) Int J Radiat Oncol Biol Phy 109, 1421]
    • EU funded trial (www.immunosabr.org), sponsored by the University of Maastricht (The Netherlands), currently involving 10 centers in The Netherlands, Belgium, and France.
    • Planned the opening of three additional centers in new countries

Dekavil

  • The product has been licensed to Pfizer
  • Philogen is involved in the clinical development program in Rheumatoid Arthritis
  • Communication activities are to be performed in agreement between the two companies

Dodekin

  • The product is developed in collaboration with a large pharmaceutical company
  • A Phase I/II monotherapy trial in patients with multiple types of cancer, who no longer respond to immunotherapy, is currently being conducted in Italy, Switzerland, and Germany, with Philogen acting as Sponsor
  • Communication activities are to be performed in agreement between the two companies

OncoFAP

  • FAPtargeting platform for the delivery of radionuclide-conjugates, drug-conjugates, bispecific immunomodulators, universal CAR-T cells
    • Radionuclide-conjugates: First-in-human data exhibiting an extremely efficient and selective targeting of both primary and metastatic lesions in cancer patients, with very rapid clearance through the kidney and no apparent normal organ liability
    • Quantitative biodistribution data published in the Proceedings of the National Academy of Sciences [Millul et al. (2021) Proc. Natl. Acad. Sci. U.S.A., 118, e2101852118]
    • Collaboration with Senn Chemical AG for the large-scale GMP production of OncoFAP-DOTAGA, in preparation for larger clinical studies
    • Curative results in murine models of cancer obtained with OncoFAP coupled to monomethyl auristatin E, supporting the development of FAP-targeted small molecule-drug conjugates (SMDCs) as an alternative to antibody-drug conjugates (ADCs)
    • Potentiation of ADCs and SMDCs by Darleukin

OncoIX

  • CAIX-targeting platform for the delivery of radionuclide-conjugates, drug-conjugates, bispecific immunomodulators, universal CAR-T cells
    • Rationale for the use of the OncoIX platform not only for radionuclide delivery and for drug delivery, but also for the creation of small molecule bispecifics and adaptors for universal CAR-T cell therapy [Pellegrino et al. (2020) Bioconj. Chem., 31,1775]

Tripokin

  • IND-enabling studies progressing
    • Clinical development program supported by excellent tumor targeting performance data and by therapy results in preclinical models of cancer [De Luca et al. (2017) Mol Cancer Ther, 16, 2442; De Luca et al., (2018) Cancer Immunol Immunother, 67, 1381].
    • The incorporation of potency-matched cytokine moieties in the same product promises to be useful for the treatment of multiple tumor types, alone or in combination with other therapeutic modalities, exploiting the function of interleukin-2 and of tumor necrosis factor
    • Stable cell line development completed
    • GMP production schedule to start in Q2 2021
    • Start of clinical trials expected in 2022

Additional preclinical programs

  • Antibody-based candidates
    • Breakthrough results in the antibody-based delivery of interferon-gamma, after many years of research in the field (patent pending).
    • Advances in research on antibody-cytokine fusion proteins with “activity-on-demand”
  • Small molecule-based candidates
    • Ligands against undisclosed tumor-associated antigens have been discovered and are currently being optimized
    • Ligands against immune cell markers have been discovered and are being optimized, with the plan to develop fully synthetic small molecule bispecific

Potentiation of the Manufacturing facilities

  • Rosia
    • Completion of the construction of a second GMP production facility on-track (expected by the end of May 2021).
    • Validation activities and production of engineering lots are planned prior to the inspection by the relevant authorities, expected in 2022
  • Montarioso
    • Planned upgrade of the existing facility, with purchase of additional equipment
    • Manufacturing activities both for in-house product development and for third parties

Financial Update

  • Philogen successfully listed on the Italian Stock Exchange on March 3rd, 2021.
  • Philogen is well capitalized, with cash & cash equivalents of about € 120 million
  • The proceeds will boost late stage programs, expand the pipeline and potentiate in house manufacturing

About Philogen

Philogen is a Swiss-Italian clinical-stage biotechnology company listed on the Italian Stock Exchange. It is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com and www.philochem.com.

ForwardLooking Statements

The forward-looking statements contained in this press release may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding anticipated advancement of preclinical development efforts and initiation and progression of clinical trials; anticipated enrollment in and progression of Philogen’s clinical trials; the availability of data from clinical trials and preclinical studies; anticipated regulatory filings; the therapeutic potential of Philogen’s product candidates; Philogen’s ability to achieve planned milestones. Philogen may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Philogen’s and its partners’ abilities to meet other anticipated deadlines and milestones, also due to the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Philogen’s product candidates by Philogen or its partners; the risk that Philogen may not realize the intended benefits of its technology; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Philogen’s product candidates; risks related to Philogen’s ability to maintain existing collaborations and realize the benefits thereof; expectations for regulatory approvals to conduct trials or to market products; other factors which could cause our actual result to differ from those contained in the forward-looking statements, as also described in greater detail in the Risk Factors section in the prospectus drafted by Philogen and approved by Consob on February 17, 2021. Any forward-looking statements contained in this press release speak only as of the date hereof, and Philogen expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. The information and contents of this press release do not: (i) constitute an order or an offer to purchase or to sell financial products or financial services; (ii) relate to special investment goals or to the financial situation or particular requirements of specific users. All information presented, reports published and opinions expressed are intended purely for information purposes, and do not constitute an offer for the conclusion of a contract or other legal transaction. In particular, the content of the press release is not to be understood as an invitation or recommendation to buy or sell securities of Philogen, or as an advertisement for securities of Philogen. Neither does it constitute an offer to participate in any other transaction, including (but not restricted to) trading in derivatives. The mere use of the website does not give rise to any contractual relationship of any kind between the user and Philogen. Philogen expressly draws your attention to the fact that its share price is subject to fluctuation, and that the future development of the share price cannot be derived either from the previous price history or from the information and content shown on this website. Results achieved in the past provide no guarantee in regard to the future development of the share price. Philogen provides no guarantee of any kind that the capital invested will increase in value or maintain its value. In light of these given risks, we strongly advise you to seek professional advice before making any investment decision. The material contained on the website does not relieve the user from having to make his own decisions. This press release may contain links to external websites of third parties (external links) the content of which is outside the sphere of influence of Philogen. Visiting and using such websites that are accessible via such links are subject to the conditions of the data protection policy of these websites and the liability of the respective operators. Philogen accepts no responsibility and offers no guarantee of any kind for the content or websites of third parties, and gives no assurances of any kind in this regard. Philogen accepts no responsibility for the data protection policy and customer information of websites of third parties, and shall not be liable for the content or web pages of third parties which are linked to the Philogen website or which display the Philogen website in frames.

Philogen contacts

Dr. Christian Lizak (Business Development), Dr. Emanuele Puca (Investor Relations)

+41 (0) 43 544 88 00

christian.lizak@philogen.comemanuele.puca@philogen.com

Consilium Strategic Communications contacts

Mary-Jane Elliott, Melissa Gardiner, Davide Salvi

Philogen@consilium-comms.com